XETRA •
Healthcare •
Biotechnology •
Quote as of 07/01/2026 17:35
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeXETRA
Market Capitalization1,643.21 mln
Float40.94 mln
Earnings Date05/06/2026
EPS
7.41
Strong
P / E
3.54
Deeply undervalued
Piotroski F-Score
6
/ 9
Solid
Beneish M-Score
0.58
Highly suspicious
Relative Strength
91
/ 100
Top performer
Debt / Equity
0.00
Debt-free
Business Description
Galapagos NV is a Belgian biotechnology company founded in 1999 that researches and develops new treatments for cancer and immune system diseases, with operations primarily in the United States and Europe. The company currently has several drugs in clinical trials, including therapies targeting conditions such as lupus, lymphoma, and multiple myeloma. Galapagos works alongside Gilead Sciences as a key partner in advancing its research.
